Comparative Pharmacology
Head-to-head clinical analysis: TRANEXAMIC ACID versus TRASYLOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRANEXAMIC ACID versus TRASYLOL.
TRANEXAMIC ACID vs TRASYLOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibitor of plasminogen activation, blocking the binding of plasminogen to fibrin, thereby preventing fibrinolysis and stabilizing clots.
Aprotinin is a serine protease inhibitor that forms reversible enzyme-inhibitor complexes with trypsin, plasmin, kallikrein, and chymotrypsin, thereby inhibiting fibrinolysis and reducing perioperative blood loss.
1 g intravenously every 8 hours for prophylaxis of bleeding in cardiac surgery; for heavy menstrual bleeding: 1.3 g orally three times daily for up to 5 days during menstruation.
1,000,000 KIU (kallikrein inhibitor units) IV loading dose over 10 minutes, followed by 250,000 KIU/hour continuous IV infusion during surgery; also 1,000,000 KIU added to cardiopulmonary bypass circuit prime volume.
None Documented
None Documented
Clinical Note
moderateTranexamic acid + Estrone sulfate
"Tranexamic acid may increase the thrombogenic activities of Estrone sulfate."
Clinical Note
moderateTranexamic acid + Estramustine
"Tranexamic acid may increase the thrombogenic activities of Estramustine."
Clinical Note
moderateTranexamic acid + Tretinoin
"Tranexamic acid may increase the thrombogenic activities of Tretinoin."
Clinical Note
moderateTranexamic acid + Diethylstilbestrol
Terminal elimination half-life approximately 2-11 hours (mean 2 hours in healthy adults; prolonged to 7-15 hours in renal impairment). Clinical context: dosing interval adjustment required in renal insufficiency.
Terminal elimination half-life approximately 2 hours (alpha phase) and 10-12 hours (beta phase); prolongation in renal impairment.
Primarily renal excretion as unchanged drug (95% within 24 hours) via glomerular filtration; minimal biliary/fecal elimination (<5%).
Primarily renal excretion; 70-80% of aprotinin is eliminated unchanged in urine within 48 hours; minor biliary/fecal elimination (<5%).
Category A/B
Category C
Antifibrinolytic
Antifibrinolytic
"Tranexamic acid may increase the thrombogenic activities of Diethylstilbestrol."